Diagnostic Utility of Glycosyltransferase mRNA Expression in Gastric Cancer
Conclusion This study revealed the potential of ppGalNAc-T6 and ST6GalNAc-I mRNA transcript levels in serum as markers of gastric cancer. Further studies on the wider range of glycosyltransferases in various cancers are needed to establish signature mRNA batteries as minimally invasive markers of gastric cancer. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - April 27, 2018 Category: Cancer & Oncology Source Type: research

Intravenous Compared to Oral Busulfan with Cyclophosphamide for Autologous Hematopoietic Cell Transplant Conditioning for Plasma Cell Myeloma
Publication date: Available online 24 April 2018 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Moaath Mustafa Ali, Donna M Corrigan, Lisa A. Rybicki, Melissa A Yurch, Kelly Cherni, Hien Liu, Robert Dean, Betty Hamilton, Brad Pohlman, Steven Andresen, Matt Kalaycio, Brian J. Bolwell, Navneet S. Majhail, Ronald Sobecks (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - April 25, 2018 Category: Cancer & Oncology Source Type: research

Vinorelbine-Cyclophosphamide compared to Cyclophosphamide in Peripheral Blood Stem Cell Mobilization for Multiple Myeloma
Conclusion Vino-Cy is a potential alternative to Cy given the need for effective mobilisation protocols with acceptable toxicity. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - April 24, 2018 Category: Cancer & Oncology Source Type: research

Sorafenib-induced tumor lysis syndrome in a patient with metastatic hepatocellular carcinoma
We describe the case of a young patient with metastatic hepatocellular cancer who developed rapid and fatal tumor lysis syndrome following initiation of sorafenib therapy. Although rare with sorafenib therapy for hepatocellular carcinoma, tumor lysis syndrome is serious complication. Patients with a high burden of disease at therapy initiation should have their metabolic parameters measured prior to starting therapy and closely followed for the first 1-2 weeks while being treated. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - April 18, 2018 Category: Cancer & Oncology Source Type: research

Plasma Cell Myeloma with Auer Rode like Inclusions
Publication date: Available online 17 April 2018 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Nour AlMozain, Tarek Owaidah (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - April 17, 2018 Category: Cancer & Oncology Source Type: research

The Relation between Protein Z Polymorphism and the Risk of Thrombosis in Egyptian Patients with Antiphospholipid Syndrome
Conclusion Protein Z-79 G/A gene polymorphism may be of a protective value against thrombosis in APS. The G79A polymorphism of protein Z was not found to be an independent risk factor of thrombosis in APS. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - April 17, 2018 Category: Cancer & Oncology Source Type: research

Predictors of Outcome in Patients With Hematologic Malignancies Admitted to The Intensive Care Unit
Conclusion overall hospital outcome of critically ill patients with HM is improving. However those who require mechanical ventilation or underwent allogeneic HSCT continue to have poor outcome. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - April 17, 2018 Category: Cancer & Oncology Source Type: research

Myeloid Sarcoma with Megakaryoblastic Differentiation Presenting as a Breast Mass
We report a case of myeloid sarcoma with megakaryoblastic differentiation in the breast of a patient with history of essential thrombocythemia. The mass was composed of undifferentiated pleomorphic malignant cells in trabecular cords and nests with many scattered giant malignant cells and brisk abnormal mitoses. On immunohistochemistry, the neoplastic cells were positive for CD61, CD31, CD34, Factor VIII and CD43 which confirmed the diagnosis. To our knowledge, this is the first report of myeloid sarcoma with megakaryoblastic morphology occurring in the breast. Here we discuss the clinicopathologic features of this rare en...
Source: Hematology Oncology and Stem Cell Therapy - April 17, 2018 Category: Cancer & Oncology Source Type: research

Allogeneic Stem Cell Transplantation for Relapsed Primary Central Nervous System Lymphoma: Is it feasible?
Publication date: Available online 16 March 2018 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Erden Atilla, Ugur Sahin, Pinar Ataca Atilla, Mustafa Merter, Elif Ozyurek, Koray Ceyhan, Sinem Civriz Bozdag Primary central nervous system lymphoma (PCNSL), has an aggressive course and in untreated patients median survival is limited to three months. For relapsed PCNSL, the treatment options are few and results are usually unsatisfactory. Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) has been widely used for treatment of relapsed/refractory NHL patients. However there are limited data whether gra...
Source: Hematology Oncology and Stem Cell Therapy - March 17, 2018 Category: Cancer & Oncology Source Type: research

Damocles ’ Syndrome Revisited: Update on the Fear of Cancer Recurrence in the Complex World of Today’s Treatments and Survivorship
Conclusion Literature on the fear of cancer recurrence has begun to emerge. However, herein we provide a unique approach through the use of a metaphor: Cicero’s story of Damocles’ sword. We aim to outline the many fear-related and emotional challenges faced by cancer survivors with an extensive review of studies demonstrating such challenges. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - February 20, 2018 Category: Cancer & Oncology Source Type: research

Effects of Two Doses of Anti-T Lymphocyte Globulin-Fresenius Given after Full-match Sibling Stem Cell Transplantation in Acute Myeloblastic Leukemia Patients Who Underwent Myeloablative Fludarabine/Busulfan Conditioning
Conclusion Dose difference of rATG-F did not influence survival parameters; however, increasing the dose to 30 mg/kg seems to be effective for reducing cGVHD with an increase in infection rate requiring close monitoring of infections in AML patients who received myeloablative fludarabine/busulfan conditioning. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - February 20, 2018 Category: Cancer & Oncology Source Type: research

Age adjusted hematopoietic stem cell transplant comorbidity index predicts survival in a T-cell depleted cohort
Conclusions Despite our small sample population, HCT-CI/Age was more discriminative to identify patients with poor outcome that might benefit from intensified management strategies or other therapeutic approaches rather than allogeneic HCT. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - February 16, 2018 Category: Cancer & Oncology Source Type: research

Coagulopathic side effect of L-asparaginase on fibrinogen level in childhood acute lymphoblastic leukemia during induction phase
Conclusion Significant reduction in fibrinogen level occurred in childhood ALL patients after treatment with L-asparaginase. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - February 14, 2018 Category: Cancer & Oncology Source Type: research

Beliefs about hydroxyurea in youth with sickle cell disease
Conclusions Beliefs about hydroxyurea correlated with HRQOL scores and adherence levels. Addressing patients’ concern about hydroxyurea and medications overall as well as routine assessment of adherence and beliefs could help to overcome adherence barriers. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - February 3, 2018 Category: Cancer & Oncology Source Type: research

Skin involvement in Burkitt ’s lymphoma
Publication date: Available online 2 February 2018 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Dhwanee Thakkar, Lipika Lipi, Ruchira Misra, Satya Prakash Yadav (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - February 3, 2018 Category: Cancer & Oncology Source Type: research

Age adjusted hematopoietic stem cell transplant comorbidity index predicts survival in a T cell depleted cohort
Conclusions Despite our small sample population, HCT-CI/Age was more discriminative to identify patients with poor outcome that might benefit from intensified management strategies or other therapeutic approaches rather than allogeneic HCT. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - February 3, 2018 Category: Cancer & Oncology Source Type: research

Acquired Amegakaryocytic Thrombocytopenia and Red Cell Aplasia in a Patient with Thymoma Progressing to Aplastic Anemia Successfully Treated with Allogenic Stem Cell Transplantation
We report a patient with thymoma complicated by pure red cell aplasia (PRCA) and AAMT who progressed to develop aplastic anemia (AA). The patient was refractory to 10-months of immunosuppressive therapy with cyclosporine, prednisone, and antithymocyte globulin. She was eventually treated with allogeneic stem cell transplantation (allo-SCT). On Day +323 the patient continues to be transfusion-independent. This case illustrates how in patients with thymoma and AAMT may herald development of AA. This is also the first report of a patient with AAMT progressing to thymoma-associated AA being successfully treated with allo-SCT. ...
Source: Hematology Oncology and Stem Cell Therapy - February 2, 2018 Category: Cancer & Oncology Source Type: research

Fecal calprotectin and serum albumin as markers of gastrointestinal graft versus host disease
Conclusion Patients with steroid-refractory GI aGVHD had higher fecal calprotectin levels and lower albumin levels than patients with steroid-responsive disease. We recommend further studies to evaluate non-invasive tests with fecal calprotectin in combination with albumin in predicting steroid refractory disease at onset of symptoms to potentially identify patients that may benefit from upfront escalation in GVHD treatment. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - February 2, 2018 Category: Cancer & Oncology Source Type: research

Ibritumomab tiuxetan (Zevalin) and elevated serum human anti-murine antibody (HAMA)
Publication date: Available online 1 February 2018 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Sarbajit Mukherjee, Adanma Ayanambakkam, Sami Ibrahimi, Sarah Schmidt, Jennifer Holter Charkrabarty, Mohamad Khawandanah Ibritumomab Tiuxetan (Zevalin) is an anti CD-20 murine monoclonal antibody linked to the radio-isotope 90-yttrium (90Y) by the chelator Tiuxetan. It is FDA approved for treatment of relapsed low grade or follicular B-cell Non-Hodgkin's Lymphoma (NHL) or newly diagnosed follicular NHL following an initial response to first-line chemotherapy. Patients may develop Human Anti-Murine Antibodies (HAM...
Source: Hematology Oncology and Stem Cell Therapy - February 2, 2018 Category: Cancer & Oncology Source Type: research

Coagulopathic Side Effect of L – asparginase on Fibrinogen Level in Childhood Acute Lymphoblastic Leukemia During Induction Phase
Publication date: Available online 1 February 2018 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Alauldeen Mudhafar Zubair Alqasim, Raji Hussein Al-Hadithi, Aseel Nashaat Al-Khalidi (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - February 2, 2018 Category: Cancer & Oncology Source Type: research

Utility of Routine Surveillance Imaging for Diffuse Large B-Cell Lymphoma Post Autologous Transplant: A Single Center Experience
Publication date: Available online 19 December 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Ghulam Rehman Mohyuddin, Ashley Elizabeth Clark, John Roller, Leyla Shune, Tara Lin, Neil Dunavin, Ajoy Dias, Siddhartha Ganguly, Sunil Abhyankar, Joseph McGuirk, Anurag Singh Surveillance scans after autologous stem cell transplant (auto-HCT) for patients with relapsed/refractory (RR) diffuse large B Cell lymphoma (DLBCL) have no proven survival benefit. We studied survival differences among patients with RR DLBCL post auto-HCT whose recurrences were detected clinically versus with routine surveillance imaging....
Source: Hematology Oncology and Stem Cell Therapy - December 20, 2017 Category: Cancer & Oncology Source Type: research

Considerations in Setting Up and Planning a Graft Processing Facility
Publication date: Available online 13 December 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Mickey B.C. Koh (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - December 14, 2017 Category: Cancer & Oncology Source Type: research

Reduced intensity is preferred over myeloablative conditioning allogeneic HCT in chronic lymphocytic leukemia whenever indicated: A systematic review/meta-analysis
We report the results in accordance to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Based on lower non-relapse mortality and slightly better overall survival rates, reduced intensity conditioning regimens appear to be the most desirable choice whenever the procedure is indicated for this disease. It appears highly unlikely that a RCT will be ever performed comparing reduced intensity vs. myeloablative allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia. In the absence of such a study, results of this systematic review/meta-analysis represent the best available...
Source: Hematology Oncology and Stem Cell Therapy - December 7, 2017 Category: Cancer & Oncology Source Type: research

Co-existence of myeloid neoplasm and monoclonal gammopathy; case series and review of literature
Publication date: Available online 6 December 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Navkirti Mittal, Ruchi Gupta, Khaliqur Rahman, Tanvi Gupta, Soniya Nityanand (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - December 7, 2017 Category: Cancer & Oncology Source Type: research

Thalassemia Major: Transplantation or Transfusion and Chelation
Publication date: Available online 20 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Said Y. Mohamed Thalassemia is the most common monogenic hematologic disease that affects millions in the world and kills thousands of patients every year. Without transfusion or transplantation, patients with thalassemia major are expected to die within months of diagnosis. However, long-term transfusion and chelation therapy is highly challenging for many developing countries where the disease is prevalent, representing a major and unsustainable health burden. Stem cell transplantation is the only cure for thalass...
Source: Hematology Oncology and Stem Cell Therapy - November 10, 2017 Category: Cancer & Oncology Source Type: research

Aging and stem cell therapy: AMPK as an applicable pharmacological target for rejuvenation of aged stem cells and achieving higher efficacy in stem cell therapy
Publication date: Available online 19 October 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Mohammadhossein Khorraminejad-Shirazi, Mohammad Farahmandnia, Bahareh Kardeh, Alireza Estedlal, Sina Kardeh, Ahmad Monabati In recent years, tissue regeneration has become a promising field for developing stem cell-based transplantation therapies for human patients. Adult stem cells are affected by the same aging mechanisms that involve somatic cells. One of the mechanisms involved in cellular aging is hyperactivation of mechanistic target of rapamycin complex 1 (mTORC1) and disruption of 5′ adenosine monop...
Source: Hematology Oncology and Stem Cell Therapy - November 3, 2017 Category: Cancer & Oncology Source Type: research

CD209-336A/G promotor polymorphism and its clinical associations in sickle cell disease Egyptian Pediatric patients
Conclusion We found no significant difference between our population of Egyptian SCD cases and controls regarding CD209 A>G polymorphism. Infections occurred more frequently among the heterozygous genotype (AG) and homozygous genotype (GG) patients. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 31, 2017 Category: Cancer & Oncology Source Type: research

Evaluation of Weekly Paclitaxel plus Carboplatin Followed by Anthracycline Chemotherapy on the Neoadjuvant Treatment of Patients with Triple-Negative Breast Cancer
Conclusion The combination of neoadjuvant chemotherapy with wP + wCb before anthracycline chemotherapy can be tolerated by patients with triple-negative breast cancer. Complete pathologic response rates were comparable with those historically seen. Careful selection of patients is fundamental as this regimen is associated with a high incidence of hematologic toxicity. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 28, 2017 Category: Cancer & Oncology Source Type: research

CD209 -336A/G Promotor Polymorphism and its Clinical Associations in Sickle cell disease Egyptian Pediatric Patients
Conclusion We found no significant difference between our population of Egyptian SCD cases and controls regarding CD209 A>G polymorphism. Infections occurred more frequently among the heterozygous genotype (AG) and homozygous genotype (GG) patients. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 26, 2017 Category: Cancer & Oncology Source Type: research

Ageing and Stem cell therapy: AMPK as an applicable pharmacological target for Rejuvenation of Aged Stem Cells and achieving higher efficacy in stem cell therapy
Publication date: Available online 19 October 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Mohammadhossein Khorraminejad-Shirazi, Mohammad Farahmandnia, Bahareh Kardeh, Alireza Estedlal, Sina Kardeh, Ahmad Monabati In recent years, tissue regeneration has become a promising field for developing stem cell-based transplantation therapies for human patients. Adult stem cells are affected by the same aging mechanisms that involve somatic cells. One of the mechanisms involved in cellular aging is hyperactivation of mechanistic target of rapamycin complex 1 (mTORC1) and disruption of 5’ adenosine monop...
Source: Hematology Oncology and Stem Cell Therapy - October 19, 2017 Category: Cancer & Oncology Source Type: research

Successful Treatment of Pure Red Cell Aplasia with High-Dose Dexamethasone after ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation
Publication date: Available online 18 October 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Rosario Varela Gomez, Goretti Vázquez Vazquez, Victor Noriega Concepcion, Andrea Galego Garcia, Concepción Andón Saavedra The literature reports an incidence of Pure Red Cell Aplasia (PRCA) ranging from 6-30% of all cases of ABO-incompatible HSCT. Although most patients resolve spontaneously after withdrawal immunosuppression, some of them require more aggressive treatment to manage this condition. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 18, 2017 Category: Cancer & Oncology Source Type: research

DNMT3A (R882) Mutation Features and Prognostic Effect in Acute Myeloid Leukemia in Coexistent with NPM1 and FLT3 Mutations
Conclusion DNMT3A R882 mutation plays an important role in CN-AML patients’ prognosis and clinical outcomes in the presence and absence of NPM1 and FLT3 mutations. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 18, 2017 Category: Cancer & Oncology Source Type: research

Limited Role of Bone Marrow Biopsy for Detection of Marrow Involvement in Patients with Hodgkin Lymphoma from the Middle East and North Africa Region
Publication date: Available online 18 October 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Moussab Damlaj, Gamal Gmati, Ghulam Syed, Tabrez Pasha, Hend Salama, Osama Ali, Khadega A. Abuelgasim, Mohsen Al-Zahrani, Ahmad Al Askar, Ayman Alhejazi (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 18, 2017 Category: Cancer & Oncology Source Type: research

Double CD38 −/CD138− negative multiple myeloma
Publication date: Available online 18 October 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Vitaliy Mykytiv, Abrar Alwaheed, Nurul Asyikin Mohd Hashim (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 18, 2017 Category: Cancer & Oncology Source Type: research

Hereditary persistence of hemoglobin F is protective against red cell sickling. A case report and brief review
We describe a case of SCD, in which a patient with high HbF level presented at a very late age (27 years old). We presume the patient’s inherently elevated HbF levels were able to compensate for the hypoxic episodes associated with SCD. The onset of symptoms was delayed as a result of elevated HbF levels. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 16, 2017 Category: Cancer & Oncology Source Type: research

Anemia in Patient with Primary Hyperoxaluria and Bone Marrow Involvement by Oxalate Crystals
We present a rare case of anaemia secondary to bone marrow infiltration by oxalate crystals and renal failure in a patient diagnosed with primary hyperoxaluria. In our case, the anaemia was recovered after the double liver and kidney transplantation, the latter was performed on two occasions after the failure of the first graft. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 16, 2017 Category: Cancer & Oncology Source Type: research

Thrombo-hemorrhagic liability in children with congenital heart diseases
Conclusion Patients with CHD—both cyanotic and acyanotic—have variable degrees of increased liability for both thrombosis and hemorrhage that represents some sort of adaptation to preserve hemostasis and to protect these patients against the clinical presentation of both thrombosis and bleeding. This is to say that CHD patients have their own point of balance between thrombogenicity and bleeding liability. Wide-scale studies are needed to detect the normal levels of different thrombohemorrhagic parameters of these patients. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 27, 2017 Category: Cancer & Oncology Source Type: research

Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light-chain amyloidosis
Conclusion We conclude that in AL, FISH abnormalities are associated with clonal burden. We found no impact of these markers on the type of organ involvement or 1-year survival. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 20, 2017 Category: Cancer & Oncology Source Type: research

Relevance of Bone Marrow Transplantation Nursing Training Program at King Faisal Specialist Hospital and Research Centre for National and Regional Nurses
Publication date: Available online 18 August 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Reguia Belkhedim (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 18, 2017 Category: Cancer & Oncology Source Type: research

Presence of FISH abnormalities is associated with plasma cell burden in light chain amyloidosis
Conclusion We conclude that in AL, FISH abnormalities are associated with clonal burden. We found no impact of these markers on the type of organ involvement or 1-year survival. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 17, 2017 Category: Cancer & Oncology Source Type: research

Impact of Vitamin D Deficiency on Increased Blood Eosinophil Counts
Conclusion Vitamin D deficiency was associated with higher blood eosinophil count. These results support the possible role of vitamin D in the eosinophil immune response. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 17, 2017 Category: Cancer & Oncology Source Type: research

Acute Promyelocytic Leukemia in a Patient with Chronic Lymphocytic Leukemia —A Case Report
Publication date: Available online 16 August 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Prajwal Boddu, Ellen Schlette, Beenu Thakral, Guillin Tang, Naveen Pemmaraju, Tapan Kadia, Alessandra Ferrajoli, Farhad Ravandi, William Wierda, Nitin Jain Chronic lymphocytic leukemia (CLL) is known to be associated rarely with myeloid malignancies such as acute myelogenous leukemia. In this article, we report an extremely rare occurrence of acute promyelocytic leukemia in a patient with CLL. A 71-year-old man first presented to our clinic with a diagnosis of CLL and worsening motor neuropathy symptoms. It was su...
Source: Hematology Oncology and Stem Cell Therapy - August 17, 2017 Category: Cancer & Oncology Source Type: research

Ruxolitinib for Secondary Hemophagocytic Lymphohistiocytosis: First Case Report
We describe a case of secondary HLH that did not respond favorably to conventional treatments. Serum inflammatory markers continued to rise significantly with clinical deterioration and worsening pancytopenia. The severe thrombocytopenia and neutropenia were deemed to have contributed to a spontaneous subdural hematoma and candidemia, respectively. Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, was then utilized as a novel salvage therapy based on available in vivo murine data at the time. Following initiation, there was improvement seen in several disease markers, including serum ferritin, lactate dehydrogenase, fibrino...
Source: Hematology Oncology and Stem Cell Therapy - August 17, 2017 Category: Cancer & Oncology Source Type: research

Multimodality Therapy Improves Survival in Intramedullary Spinal Cord Metastasis of Lung Primary
Conclusion Lung cancer is the predominant cause of intramedullary involvement of the spinal cord. Overall prognosis is poor, although a multimodality approach was associated with improved survival. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 17, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic stem cell transplantation for sickle cell disease: The changing landscape
Publication date: Available online 15 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Adetola A. Kassim, Deva Sharma Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative therapy for sickle cell disease (SCD); however, its use is limited by lack of suitable human leukocyte antigen (HLA)-matched donors and decreased application in older patients with significant morbidity. Myeloablative, HLA-identical sibling transplantation in children with SCD offers excellent long-term survival, with overall and event-free survival rates of 95% and 92%, respectively. However, the risk ...
Source: Hematology Oncology and Stem Cell Therapy - August 2, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic stem cell transplantation in Pakistan – country report
Publication date: Available online 22 July 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Parvez Ahmed, Tahir Sultan Shamsi, Salman Naseem Adil, Tariq Mahmood Satti, Qamar un Nisa Chaudhry, Syed Kamran Mahmood, Kamran Rashid, Saqib Ansari, Natasha Ali, Tariq Ghafoor (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 27, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic Stem Cell Transplantation in Pakistan - Country Report
Publication date: Available online 22 July 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Parvez Ahmed, Tahir Sultan Shamsi, Salman Naseem Adil, Tariq Mahmood Satti, Qamar un Nisa Chaudhry, Syed Kamran Mahmood, Kamran Rashid, Saqib Ansari, Natasha Ali, Tariq Ghafoor (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 23, 2017 Category: Cancer & Oncology Source Type: research

Current Concepts on Hematopoietic Stem Cell Transplantation Outcome Registries; Emphases on Resource Requirements for New Registries
Publication date: Available online 19 July 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Fazal Hussain, Naeem Chaudhri, Feras Alfraih, Mahmoud Aljurf There is tremendous variability in size, scope, and resource requirements for registries depending on the number of patients and participating sites. The outcome registries are organized systems to collect uniform data using an observational study methodology. Patient registries are used to determine specified outcomes for a population for predetermined scientific, clinical, or policy purposes. Historically, outcome registries established in the developmen...
Source: Hematology Oncology and Stem Cell Therapy - July 20, 2017 Category: Cancer & Oncology Source Type: research

Cost and Quality Issues in Establishing Hematopoietic Cell Transplant Program in Developing Countries
Publication date: Available online 14 July 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Shahrukh K. Hashmi, Alok Srivastava, Walid Rasheed, Salman Adil, Tong Wu, Madan Jagasia, Amr Nassar, William Y.K. Hwang, Amir Ali Hamidieh, Hildegard T. Greinix, Marcelo C. Pasquini, Jane F. Apperley, Mahmoud Aljurf The hematopoietic cell transplant (HCT) activity has grown significantly over the past two decades in both developing and developed countries. Many challenges arise in establishing new HCT programs in developing countries, due to scarcity of resources and manpower in expertise in HCT. While cost issues c...
Source: Hematology Oncology and Stem Cell Therapy - July 15, 2017 Category: Cancer & Oncology Source Type: research

Complications of hematopoietic stem cell transplantation: Bacterial infections
Publication date: Available online 3 July 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Ali S. Omrani, Reem S. Almaghrabi Bacterial infections remain a common complication of hematopoietic stem cell transplantation (HSCT), especially in the pre-engraftment phase. The risk of bacterial infections is mainly related to neutropenia, mucositis, and the presence of vascular lines. Most parts of the world have witnessed a shift in epidemiology toward Gram-negative bacteria; a large proportion of which are resistant to fluoroquinolones, extended-spectrum beta-lactams, carbapenems, and in some units even colisti...
Source: Hematology Oncology and Stem Cell Therapy - July 12, 2017 Category: Cancer & Oncology Source Type: research